Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00002850 | Antibiotic Therapy in Preventing Early Infection in Patients With Multiple Myeloma Who Are Receiving Chemotherapy | completed | Phase 3 | 212 | Gary MorrowOTHER | 3 | Nov 11, 2015 | clinicaltrials |
| NCT00103506 | Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma | completed | Phase 3 | 646 | Janssen Research & Development, LLCINDUSTRY | 17 | Oct 19, 2015 |
| NCT01621672 | UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma | completed | Phase 3 | 42 | University of ArkansasOTHER | 1 | Oct 19, 2015 | clinicaltrials |
| NCT00111748 | UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients | completed | Phase 3 | 180 | University of ArkansasOTHER | 1 | Oct 6, 2015 | clinicaltrials |
| NCT00057564 | A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma | completed | Phase 3 | 470 | Celgene CorporationINDUSTRY | 16 | Sep 11, 2015 | clinicaltrials |
| NCT00217438 | Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II-III Multiple Myeloma | completed | Phase 3 | 130 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 21, 2015 | clinicaltrials |
| NCT00398411 | Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells(MoxiProph) | completed | Phase 3 | 66 | University of CologneOTHER | 1 | Jun 29, 2015 | clinicaltrials |
| NCT00434161 | A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma | completed | Phase 3 | 281 | Swedish Orphan BiovitrumINDUSTRY | 1 | Mar 30, 2015 | clinicaltrials |
| NCT00064038 | S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma | completed | Phase 3 | 198 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 25, 2015 | clinicaltrials |
| NCT00002548 | SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma | completed | Phase 3 | 899 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00416273 | A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma | completed | Phase 3 | 217 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00416208 | Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma | completed | Phase 3 | 154 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02288741 | Tandem Melphalan and Autolog. SCT in MM Patients 60 to 70 Years of Age With and Without Induction Chemotherapy(DSMM-II) | completed | Phase 3 | 549 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 0 | Nov 11, 2014 | clinicaltrials |
| NCT01160380 | A Study of the Effectiveness of Armodafinil to Treat Cancer-Related Fatigue in Patients With Multiple Myeloma | completed | Phase 3 | 50 | OncotherapeuticsINDUSTRY | 1 | Nov 6, 2014 | clinicaltrials |
| NCT00813150 | Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma | completed | Phase 3 | 96 | Janssen-Cilag G.m.b.HINDUSTRY | 1 | Aug 15, 2014 | clinicaltrials |
| NCT00507416 | Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone(UPFRONT) | completed | Phase 3 | 502 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | May 1, 2014 | clinicaltrials |
| NCT00103662 | Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients | completed | Phase 3 | 302 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Mar 13, 2014 | clinicaltrials |
| NCT00218855 | Thalidomide to Patients With Previously Untreated Multiple Myeloma | completed | Phase 3 | 363 | Norwegian University of Science and TechnologyOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00205751 | Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy | completed | Phase 2 / Phase 3 | 350 | Austrian Forum Against CancerOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00205764 | Tandem High Dose Melphalan Versus Triple Intermediate Dose Melphalan and Stem Cell Transplantation in Induction Phase and Prednisolone/IFN Versus IFN in Maintenance Therapy | completed | Phase 3 | 212 | Austrian Forum Against CancerOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01110824 | Prevention of Left Ventricular Dysfunction During Chemotherapy(OVERCOME) | completed | Phase 3 | 90 | Hospital Clinic of BarcelonaOTHER | 1 | Nov 15, 2013 | clinicaltrials |
| NCT00934154 | Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma | completed | Phase 3 | 122 | Cigdem Sahinbas YILMAZINDUSTRY | 1 | Aug 15, 2013 | clinicaltrials |
| NCT00480363 | QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smoldering Multiple Myeloma With High Risk of Progression(QUIREDEX) | completed | Phase 3 | 120 | PETHEMA FoundationOTHER | 1 | Jul 31, 2013 | clinicaltrials |
| NCT00090493 | Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma | completed | Phase 2 / Phase 3 | 4 | University of ArkansasOTHER | 1 | Jun 24, 2013 | clinicaltrials |
| NCT00002556 | Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma | completed | Phase 3 | 312 | National Cancer Institute (NCI)NIH | 1 | May 31, 2013 | clinicaltrials |
| NCT01801436 | A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma | completed | Phase 3 | 14 | Johnson & Johnson Taiwan LtdINDUSTRY | 0 | May 16, 2013 | clinicaltrials |
| NCT00420849 | A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 587 | Celgene CorporationINDUSTRY | 5 | May 21, 2012 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
| NCT00048230 | PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 3 | 620 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
| NCT00063726 | A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039 | completed | Phase 3 | 600 | Millennium Pharmaceuticals, Inc.INDUSTRY | 13 | Jan 13, 2012 | clinicaltrials |
| NCT00478777 | A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 150 | Celgene CorporationINDUSTRY | 1 | Nov 3, 2011 | clinicaltrials |
| NCT00722566 | A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma | completed | Phase 3 | 222 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Oct 10, 2011 | clinicaltrials |
| NCT00443235 | GEM05 for Patients With Multiple Myeloma More Than 65 Years Old | completed | Phase 3 | 260 | PETHEMA FoundationOTHER | 1 | Sep 19, 2011 | clinicaltrials |
| NCT00546780 | A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse(BMS TIME-1) | completed | Phase 3 | 31 | Bristol-Myers SquibbINDUSTRY | 2 | Jun 28, 2011 | clinicaltrials |
| NCT00344422 | Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 198 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Jun 10, 2011 | clinicaltrials |
| NCT00270101 | The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma | completed | Phase 3 | 156 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00270166 | The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy | completed | Phase 3 | 201 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT01296503 | Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma | completed | Phase 3 | 213 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 1 | Feb 15, 2011 | clinicaltrials |
| NCT00602511 | Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma | completed | Phase 3 | 300 | Nordic Myeloma Study GroupOTHER | 3 | Feb 9, 2011 | clinicaltrials |
| NCT00083876 | D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma | completed | Phase 3 | 500 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00093028 | Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II | completed | Phase 3 | 315 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00417911 | Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients | completed | Phase 3 | 400 | Nordic Myeloma Study GroupOTHER | 5 | Jun 22, 2010 | clinicaltrials |
| NCT01016548 | Evaluation of Influenza H1N1 Vaccine in Adults With Lymphoid Malignancies on Chemotherapy | completed | Phase 3 | 42 | University Health Network, TorontoOTHER | 1 | Jun 4, 2010 | clinicaltrials |
| NCT00222053 | IFM 99-02 Thalidomide in Myeloma | completed | Phase 3 | 800 | University Hospital, ToulouseOTHER | 1 | Apr 2, 2010 | clinicaltrials |
| NCT00179647 | Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 1,913 | Celgene CorporationINDUSTRY | 2 | Mar 16, 2010 | clinicaltrials |
| NCT01085058 | Predictive Value of the "Cytocapacity Test" Patients With Lymphoproliferative Diseases and High-dose Therapy(CU01) | completed | Phase 2 / Phase 3 | 169 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 0 | Mar 11, 2010 | clinicaltrials |
| NCT01070862 | Multiple Myeloma Treated With Thalidomide Before Autotransplant or With Conventional Chemotherapy and as Consolidation/Maintenance Treatment in Young and Elderly Patients : 3 Randomized Studies.(MAG 2002) | completed | Phase 3 | — | University Hospital, CaenOTHER | 1 | Feb 18, 2010 | clinicaltrials |
| NCT00461747 | GEM05 for Patients With Multiple Myeloma Under 65 Years(GEM05MENOS65) | completed | Phase 3 | 390 | PETHEMA FoundationOTHER | 1 | Sep 18, 2009 | clinicaltrials |
| NCT00950768 | Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients | completed | Phase 3 | 298 | Azienda Ospedaliera San Giovanni BattistaOTHER | 0 | Aug 3, 2009 | clinicaltrials |
| NCT00111319 | VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma | completed | Phase 3 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 26, 2009 | clinicaltrials |
Data updated 22 days agoSource updated Nov 11, 2015source: clinicaltrials